Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Alteon amends ACTION II trial

Dec. 4, 1996

Cholesterol-lowering activity reported for Yamanouchi LTD4 antagonist

Dec. 4, 1996

New bisphosphonic acid derivatives from Nippon Chemiphar

Dec. 4, 1996

Novel antiobesity drug filed for approval

Dec. 3, 1996

Osiris licenses inducing molecule involved in cartilage formation

Dec. 3, 1996

Cathepsin B and L inhibitors described by Nippon Chemiphar

Dec. 3, 1996

Patent issued for method of diagnosing and treating impotence

Dec. 2, 1996

Antihyperlipidemic agents from natural source described by Takeda

Dec. 2, 1996

Potent ACAT inhibitor discovered by Kitasato Institute

Dec. 2, 1996

Lilly research into antiobesity proteins continues

Dec. 2, 1996

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...